Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | AXL | P30530 | 4/20 | 0.36 |
| ▸ | CDK8 | P49336 | 2/20 | 0.36 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 2/20 | 0.33 |
| ▸ | GAK | O14976 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | SGK1 | O00141 | 4/20 | 0.31 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.31 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.31 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.31 |
| ▸ | BMP4 | P12644 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13745690 | 0.90 | GSK3B (0.34) | GSK3BAXLCDK8TNIKKDM4E | |
| SCHEMBL13745686 | 0.88 | KDR (0.35) | GSK3BAXLCDK8TNIKKDR | |
| SCHEMBL13745726 | 0.87 | BRD4 (0.37) | GSK3BKDRCAMKK2 | |
| SCHEMBL13746273 | 0.87 | GSK3B (0.35) | GSK3BAXLCDK8TNIKKDR | |
| SCHEMBL13745703 | 0.87 | KDR (0.38) | GSK3BAXLCDK8TNIKKDR | |
| SCHEMBL13745732 | 0.86 | KDR (0.49) | KDRPTPN11 | |
| SCHEMBL13746292 | 0.85 | GSK3B (0.34) | GSK3BAXLCDK8TNIKPTPN11 | |
| SCHEMBL13746071 | 0.85 | PTGER1 (0.35) | GSK3B | |
| SCHEMBL13746207 | 0.84 | ALOX5 (0.37) | GSK3BALDH1A1 | |
| SCHEMBL13745780 | 0.83 | CAMKK2 (0.41) | KDRGAKCAMKK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | MAPKAPK2, MAPK1, MAPKAPK3 | GSK3B 227/4885AXL 3999/4885CDK8 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.